Clinical AI's Accuracy Question Was Never the Whole Question
FDA's own framework gaps show interaction risk matters as much as accuracy, but the on-premise architecture fix now circulating is a contested proposal, not a settled control.
The Clinical AI Governance Gap Is Structural, Not Accidental
The regulatory perimeter around clinical AI is contested by design, and the same gap is opening upstream in drug development.
